• enVVeno Medical won FDA investigational device exemption clearance to launch a U.S. pivotal study of its non-surgical replacement venous valve.
• Company described it as first FDA IDE granted for a U.S. pivotal trial of a non-surgical replacement venous valve, targeting treatment for deep venous insufficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enVVeno Medical Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605120902ACCESSWRNAPR_____1166040) on May 12, 2026, and is solely responsible for the information contained therein.